论文部分内容阅读
目的 探讨膀胱癌中多药耐药基因 (MDR1)与 p5 3基因表达的临床意义。 方法 采用免疫组化 (SABC)法对 35例膀胱移行细胞癌中MDR1表达产物P GP与p5 3基因产物 p5 3蛋白进行了检测。结果 35例膀胱移行细胞癌中P GP、p5 3阳性率分别为 40 %和 48 6 % ,随膀胱癌的病理分级和临床分期而增高。T2 ～T4 期同Tis～T1期相比 ,MDR1及p5 3的表达均有显著性差异。MDR1与p5 3的表达无相关性。同时表达MDR1及 p5 3的患者预后较差。 结论 膀胱癌中MDR1与p5 3的表达无相关性。临床检测MDR1及p5 3可对膀胱癌患者提供更多的预后信息。
Objective To investigate the clinical significance of multidrug resistance gene (MDR1) and p5 3 gene expression in bladder cancer. Methods Immunohistochemistry (SABC) method was used to detect the expression of pGP3 and p5 3 protein in 35 cases of bladder transitional cell carcinoma. Results The positive rates of P GP and p5 3 in bladder transitional cell carcinoma of 35 cases were 40% and 48 6%, respectively, which were increased with the pathological grading and clinical stage of bladder cancer. Compared with Tis ~ T1 phase, the expression of MDR1 and p5 3 in T2 ~ T4 phase were significantly different. MDR1 and p5 3 expression no correlation. Patients with both MDR1 and p5 3 also have a worse prognosis. Conclusion There is no correlation between the expression of MDR1 and p5 3 in bladder cancer. Clinical detection of MDR1 and p5 3 provides more prognostic information to patients with bladder cancer.